Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.7 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jeevan Scientific Technology Limited reported its audited results for the quarter and year ended March 31, 2025, with the board meeting held on May 30, 2025. Standalone revenue rose about 13% year-on-year to ₹4,361 lakhs, while consolidated revenue grew roughly 18% to ₹4,684 lakhs. The company swung to a profit at the PAT level, posting ₹73.6 lakhs standalone (vs a loss of ₹105 lakhs last year) and ₹5.9 lakhs consolidated (vs a loss of ₹132.7 lakhs), though Q4 alone remained in the red on both bases. Statutory auditor Pavuluri & Co. issued an unqualified opinion on both standalone and consolidated accounts. The board appointed KP & Associates as internal auditor for FY26 and Aakanksha Dubey & Co. as secretarial auditor for five years, and accepted the resignation of COO Chakrapani Majumdar citing personal commitments.
The return to profitability and clean audit opinion are positives, but the absolute profit is thin, the Q4 quarter was loss-making, and consolidated borrowings roughly doubled while the COO exits - so investors should watch for continuity of operations and follow-up quarters.